Safety Assessment of Inactivated Whole Virion Booster Vaccine against the SARS­-CoV-­2 Virus (BelCovidVac) in Immunized Study Subjects aged 18 to 60 Years (day 28)

I. Stoma, E. Voropaev, E. I. Mikhailova, D. M. Los’, O. Osipkina, A. Y. Braga, A. Kovalev, A. V. Molchanova, N. V. Trofimova, O. S. Pershenkova, B. S. Yaroshevich, M. N. Mirge
{"title":"Safety Assessment of Inactivated Whole Virion Booster Vaccine against the SARS­-CoV-­2 Virus (BelCovidVac) in Immunized Study Subjects aged 18 to 60 Years (day 28)","authors":"I. Stoma, E. Voropaev, E. I. Mikhailova, D. M. Los’, O. Osipkina, A. Y. Braga, A. Kovalev, A. V. Molchanova, N. V. Trofimova, O. S. Pershenkova, B. S. Yaroshevich, M. N. Mirge","doi":"10.31631/2073-3046-2024-23-3-107-119","DOIUrl":null,"url":null,"abstract":"Relevance. According to the World Health Organization (WHO), it is not yet possible to effectively stop the spread of new strains of coronavirus [1]. At the same time, most experts and analysts in the field of medicine publicly admit that at the moment vaccination is the most powerful weapon in the fight against COVID-19 [2–6]. While vaccination, like the entire health care system, has now become an element of politics and economics, the creation of proprietary vaccine in each country has become an element of national security [7]. Aims. To evaluate the safety of the inactivated booster vaccine «BelCovidVac» in immunized study subjects from 18 to 60 years old (day 28). Materials and methods. A prospective, randomized, double-blind phase I/II trial evaluated the safety of an inactivated whole virion booster vaccine against the SARS-CoV-2 virus in two doses in healthy study subjects aged 18 to 60 years who had completed a full course of vaccination with the SARS-CoV-2 virus and/or recovered from COVID-19, which included 129 subjects (24 in phase 1 and 105 in phase 2). Results. The study reported 195 adverse reactions in 94 study subjects. The study reported 80 adverse reactions in 24 (100%) study subjects at Phase 1, and 115 adverse reactions in 70 subjects at Phase 2. The study detected mild adverse reactions in 77,50% of cases at Phase 1, and in 71,30% at Phase 2. Moreover, the study found one serious adverse reaction in 1 subject at Phase 2, which occurred as a result of taking placebo. The incidence of adverse reactions with the use of the candidate vaccine in two doses is comparable to placebo (2 = 3,15, p = 0,08). Conclusion. The vaccine candidate demonstrated good tolerability at both Phase 1 and Phase 2.","PeriodicalId":11736,"journal":{"name":"Epidemiology and Vaccinal Prevention","volume":"30 22","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiology and Vaccinal Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31631/2073-3046-2024-23-3-107-119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Relevance. According to the World Health Organization (WHO), it is not yet possible to effectively stop the spread of new strains of coronavirus [1]. At the same time, most experts and analysts in the field of medicine publicly admit that at the moment vaccination is the most powerful weapon in the fight against COVID-19 [2–6]. While vaccination, like the entire health care system, has now become an element of politics and economics, the creation of proprietary vaccine in each country has become an element of national security [7]. Aims. To evaluate the safety of the inactivated booster vaccine «BelCovidVac» in immunized study subjects from 18 to 60 years old (day 28). Materials and methods. A prospective, randomized, double-blind phase I/II trial evaluated the safety of an inactivated whole virion booster vaccine against the SARS-CoV-2 virus in two doses in healthy study subjects aged 18 to 60 years who had completed a full course of vaccination with the SARS-CoV-2 virus and/or recovered from COVID-19, which included 129 subjects (24 in phase 1 and 105 in phase 2). Results. The study reported 195 adverse reactions in 94 study subjects. The study reported 80 adverse reactions in 24 (100%) study subjects at Phase 1, and 115 adverse reactions in 70 subjects at Phase 2. The study detected mild adverse reactions in 77,50% of cases at Phase 1, and in 71,30% at Phase 2. Moreover, the study found one serious adverse reaction in 1 subject at Phase 2, which occurred as a result of taking placebo. The incidence of adverse reactions with the use of the candidate vaccine in two doses is comparable to placebo (2 = 3,15, p = 0,08). Conclusion. The vaccine candidate demonstrated good tolerability at both Phase 1 and Phase 2.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在 18 至 60 岁的免疫研究对象中进行非活性全病毒 SARS-CoV-2 强化疫苗(BelCovidVac)的安全性评估(第 28 天)
相关性。据世界卫生组织(WHO)称,目前尚无法有效阻止冠状病毒新毒株的传播[1]。同时,医学领域的大多数专家和分析家都公开承认,目前接种疫苗是抗击 COVID-19 的最有力武器 [2-6]。虽然疫苗接种与整个医疗保健系统一样,现在已成为政治和经济因素,但各国研制专有疫苗已成为国家安全因素[7]。目的。评估灭活强化疫苗 "BelCovidVac "在 18 至 60 岁(第 28 天)免疫研究对象中的安全性。材料和方法一项前瞻性、随机、双盲 I/II 期试验评估了针对 SARS-CoV-2 病毒的灭活全病毒强化疫苗的安全性,该疫苗分为两剂,接种对象为 18 至 60 岁的健康受试者,这些受试者已完成 SARS-CoV-2 病毒的全程接种和/或从 COVID-19 中康复,共包括 129 名受试者(第一期 24 名,第二期 105 名)。研究结果该研究报告了 94 名研究对象的 195 例不良反应。研究报告显示,第 1 阶段有 24 名受试者(100%)出现 80 例不良反应,第 2 阶段有 70 名受试者出现 115 例不良反应。研究发现,第一阶段有 77.50%的病例出现轻微不良反应,第二阶段有 71.30%的病例出现轻微不良反应。此外,研究还发现,第 2 阶段有 1 名受试者因服用安慰剂而出现严重不良反应。两剂候选疫苗的不良反应发生率与安慰剂相当(2 = 3.15,p = 0.08)。结论候选疫苗在第一和第二阶段均表现出良好的耐受性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Serogroup B Protein Meningococcal Vaccines and the Formation of Immune Protection against Gonorrhea Obtaining and Characterization of Experimental Diagnostic Brucellosis Rabbit Sera for the Development of a National Standard for Brucellosis Serum New Russian Trivalent Hepatitis B Vaccine (Bubo®­-Unigep): Reactogenicity, Safety and Immunological Efficacy Bacterial Infections Transmitted by Ticks in Barnaul: Epidemiological and Epizootological Situation, Diagnostic Problems Factors Determining Adherence to Hand Antisepsis by Healthcare Workers during Pandemic Infection Spread (as exemplified by COVID­-19)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1